Josh Enomoto

Josh Enomoto

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

7 EV Stocks to Buy as the Sector Races for a Recovery

While seemingly everyone was talking about the electrification of mobility, a forced pit stop might yield a more favorable entry point for EV stocks to…

The Top 3 Stocks to Buy for a Profitable Eco-Friendly Portfolio

In prior paradigms, the idea of eco-friendly stocks would probably have been met with ridicule, if not outright derision. Back in the good ole days,…

3 Top-Rated Tech Stocks Wall Street Analysts Are Loving Now: January 2024

While digital innovation served as the backbone of last year’s resilient market performance, investors moving forward may want to concentrate on top-rated tech stocks. Specifically,…

7 Cryptos to Watch as the Floodgates Are Set to Open

After much anticipation and drama, the world turned to cryptos to watch as the blockchain industry finally got a spot-virtual currency exchange-traded fund (ETF) on…

7 High-Yield Dividend Stocks That Will Thrive as Interest Rates Drop

If the will-it-or-won’t-it game that the Federal Reserve is playing tips the hat toward monetary policy doves, then investors really ought to consider high-yield dividend…

PayPal (PYPL) Stock Dips on Mizuho Downgrade

Although Mizuho analysts downgraded PayPal based on competitive concerns, the red ink in PYPL stock could attract contrarians.

Why Is Elevai Labs (ELAB) Stock Up Today?

Elevai Labs is soaring on an intriguing licensing agreement with INmune Bio, but the narrative presents a mixed bag for ELAB stock.

The 3 Most Undervalued Value Stocks to Buy in January

With Wall Street jubilant about avoiding a recession last year, investors may want to continue betting on the same horse, although here’s the thing: targeting…

3 Cybersecurity Stocks to Buy as Digital Threats Continue to Grow

While seemingly everyone loves talking about the dramatic advancements in technology in recent years, investors ought to consider the caboose of this freight train: cybersecurity…

7 Undervalued Stocks to Buy for the Contrarian Investor

With the equities sector avoiding a much-dreaded recession in 2023 and subsequently rising to unprecedented heights, investors may be better served rotating into undervalued stocks.…